+ Watch LXRX
on My Watchlist
A biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.
In late June Lexicon announced positive results from the phase IIb trial of glucose transporter inhibitor LX4211. I don't really have a complaint about the data. It looks good. But the study doesn't clearly establish where LX4211 might fit into diabetes management, a rapidly evolving field with numerous proprietary and generic therapies available. I think when Lexicon has a positive catalyst, investors sometimes forget about their enormous 480M share count and concurrent bloated market cap. When the share price hit 3.2, the market cap approached 1.5B. That's quite a chunk of change for LX4211 and some other less inspiring pipeline candidates, and a hard level of interest to maintain in the years ahead before LX4211 can be commercialized.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions